Please login to the form below

Not currently logged in
Email:
Password:

BiTE

This page shows the latest BiTE news and features for those working in and with pharma, biotech and healthcare.

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

Infection leads to symptomatic disease in up to 97% of people after three to seven days following the mosquito bite, with clinical symptoms including fever, joint and muscle pain, headache, nausea

Latest news

More from news
Approximately 1 fully matching, plus 111 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 22 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
nzyme

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...